The QualityStocks Daily Friday, August 31st, 2018

Today's Top 3 StockMarketWatch

MoneyTV (SPRV) +100.00%

StockMarketWatch (AOBC) +43.60%

CannabisNewsWire (GRYN) +43.20%

The QualityStocks Daily Stock List

HealthLynked Corp. (HLYK)

OTC Markets and InvestorsHub reported on HealthLynked Corp. (HLYK), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

HealthLynked Corp. centers on improving healthcare services for patients and physicians. Its technology lessens wait times with online scheduling of appointments and real-time appointments by local providers. Furthermore, the Company’s technology provides easy access to an individual’s and their family’s updated medical records. HealthLynked has its corporate headquarters in Naples, Florida.

The Company concentrates on improving healthcare through connecting patients with their healthcare providers. The HealthLynked Network focuses on the efficient, secure exchange of medical information between patients and their healthcare providers. The cloud-based HealthLynked Network lets patient's medical records move with them. This is so one’s medical records are not fragmented in manifold healthcare systems and/or EHR (Electronic Health Record) systems.

The HealthLynked Healthcare Summary permits patients to maintain a complete medical profile in coordination with physicians. All information is systematically categorized. As a result, physicians have a total overview of patient health without them having to fill unnecessary paperwork.

HealthLynked profile information safeguards that doctors don't prescribe potentially harmful medications in case a patient forgets to mention one or more present medications while talking to their doctor. Moreover, the HealthLynked Healthcare Summary page enables patients to keep their medical records updated. This helps physicians to be more productive and provide valid medical care.

In August, HealthLynked announced the release of its latest software upgrade to the Company’s network, which allows physicians to connect with other physicians across the country. The new service facilitates and encourages several critical interactions among healthcare providers that can substantiallly improve patient care.

This application enables healthcare providers to “lynk” to one another through HealthLynked’s online directory of more than 880,000 healthcare providers in the U.S. Upon being connected, physicians can communicate through online messages or in real time through the Company’s online chat feature. They can also can share files, medical articles and can engage in group discussions with numerous physicians.

Last week, HealthLynked announced the launch of its mobile app for Android™ mobile devices, which connects patients (users/members) with their healthcare providers. Its application permits members to access their HealthLynked profile and medical information while in transit, eliminating redundant paperwork and the need to carry physical medical records and insurance cards to physician office visits.

HealthLynked Corp. (HLYK), closed Friday's trading session at $0.35, up 3.08%, on 96,342 volume with 25 trades. The average volume for the last 60 days is 268,183 and the stock's 52-week low/high is $0.03/$0.65.

chart

NXT Energy Solutions, Inc. (NSFDF)

Serious Traders, SmarTrend Newsletters, Vantage Wire, StockOoodles, and Streetwise Reports reported previously on NXT Energy Solutions, Inc. (NSFDF), and we highlight the Company as well, here at the QualityStocks Daily Newsletter.

NXT Energy Solutions, Inc. is a technology business. The Company’s proprietary Stress Field Detection (SFD®) survey system uses quantum-scale sensors to detect gravity field perturbations in an airborne survey method that can be used onshore and offshore to remotely identify areas with exploration potential for traps and reservoirs. Established in 1994, NXT Energy Solutions is headquartered in Calgary, Alberta.

The Company’s unique geophysical service is for the upstream oil & gas industry. SFD® is environmentally friendly. It is unaffected by ground security issues or difficult terrain. SFD® is an airborne tool. It provides information on areas favorable to fluid entrapment in the sedimentary column. The SFD® survey is complementary to existing geophysical methods, especially seismic programs.

NXT Energy Solutions provides its clients with an effective and reliable method to lessen time, costs, and risks related to exploration. The SFD® survey system allows its clients to focus their hydrocarbon exploration decisions concerning land commitments, data acquisition expenditures, and prospect prioritization on areas with the greatest potential.

SFD®, in pre-seismic applications, can produce high-potential prospect leads in large underexplored regions. In post-seismic applications, SFD® can prioritize seismic prospects based on their reservoir potentials.

In January 2018, NXT Energy Solutions announced the first worldwide patent of the Stress Field Detection (SFD®) Technology and the development of a new generation of sensors, which will enhance the Company’s ability to provide higher quality survey results. NXT is negotiating commercial contracts for the application of its proprietary SFD® oil & gas exploration method with governments, national oil companies, and other industry participants.

Recently, NXT Energy Solutions announced its financial and operating results for the quarter-ended June 30, 2018. No survey Revenues were recorded for the first two quarters of 2018. A Net Loss of $1.96 million was recorded for the three months ended June 30, 2018.  A Net Loss of $3.92 million was recorded for the six months ended June 30, 2018.

NXT Energy Solutions, Inc. (NSFDF), closed Friday's trading session at $0.5698, down 3.08%, on 20,491 volume with 10 trades. The average volume for the last 60 days is 16,161 and the stock's 52-week low/high is $0.317/$1.05.

chart

Acura Pharmaceuticals, Inc. (ACUR)

CRWEWallStreet, PennyToBuck, StreetInsider, Marketbeat, SmarTrend Newsletters, Wall Street Resources, PennyOmega, PennyStocks24, Penny Stock Rumble, The Street, BestOtc, BUYINS.NET, CRWEFinance, StockHotTips, and DrStockPick reported on Acura Pharmaceuticals, Inc. (ACUR), and today we report on the Company, here at the QualityStocks Daily Newsletter.

Acura Pharmaceuticals, Inc. is a specialty pharmaceutical company innovating abuse deterrent drugs. It engages in the research, development, and commercialization of product candidates intended to address medication abuse and misuse, utilizing its proprietary LIMITx™, AVERSION®, and IMPEDE® Technologies. OTCQB-listed, Acura Pharmaceuticals is based in Palatine, Illinois.

The patented LIMITx technology works by neutralizing stomach acid with buffering ingredients as increasing numbers of tablets are swallowed. It relies on stomach acid to play a role in the release and subsequent systemic absorption of the active ingredient from micro-particles contained in the tablets.

The intention of the LIMITX™ Technology is to address an oral Excessive Tablet Abuse (ETA) or accidental consumption of multiple tablets and provide a margin of safety during accidental over-ingestion of tablets. Additionally, LIMITX™ is expected to exhibit barriers to abuse by snorting and injection. LTX-04 is Acura’s lead development candidate employing its novel LIMITx™ technology.

AVERSION® Technology is a patented composition of commonly used active and inactive pharmaceutical ingredients providing abuse deterrent features and benefits for orally administered pharmaceutical drug products. The intention of AVERSION® Technology opioid analgesic product candidates is to provide effective relief from pain. This is while discouraging common methods of pharmaceutical product misuse and abuse.

OXAYDO® (oxycodone HCl immediate-release tablets), which incorporate the AVERSION Technology, is Food and Drug Administration (FDA) approved and marketed in the United States by Acura’s partner Egalet Corp.

The IMPEDE® Technology platform is an advanced polymer matrix. It is used in NEXAFED®, Acura Pharmaceuticals’ pseudoephedrine (PSE) tablet product, to limit or disrupt the extraction of PSE from tablets for conversion into the illicit drug methamphetamine.

NEXAFED® and NEXAFED® Sinus are pseudoephedrine containing products that use the IMPEDE Technology. They are marketed in the United States by Acura Pharmaceuticals’ partner MainPointe Pharmaceuticals.

This month, Acura Pharmaceuticals announced financial results for the three and six months ended June 30, 2018. Acura reported a Net Loss of $2.8 million or $0.13 per diluted share for the six months ended June 30, 2018, versus a Net Loss of $1.7 million or $0.15 per diluted share for the same period in 2017. For the Q2 2018, it reported a Net Loss of $1.3 million or $0.06 per diluted share versus a Net Loss of $2.2 million or $0.18 per diluted share for the same period in 2017.

Acura Pharmaceuticals, Inc. (ACUR), closed Friday's trading session at $0.12, down 14.29%, on 24,855 volume with 11 trades. The average volume for the last 60 days is 15,437 and the stock's 52-week low/high is $0.10/$0.8702.

chart

MYM Nutraceuticals, Inc. (MYMMF)

Stockhouse, MarketWatch, OTC Markets, Barchart, Investing, InvestorsHub, and Market News Updates reported on MYM Nutraceuticals, Inc. (MYMMF), and today we report on the Company, here at the QualityStocks Daily Newsletter.

MYM Nutraceuticals, Inc. focuses on acquiring Health Canada licenses to produce and sell high-end organic medicinal cannabis supplements and topical products. The Company is looking to acquire complementary businesses and assets in the technology, nutraceuticals, and CBD sectors. MYM is the sole owner of CBD brands HempMed, Joshua Tree, and Dr. Furbaby. MYM Nutraceuticals is based in Vancouver, British Columbia.

Dr. Furbaby is the Company’s CBD line of products specifically for pets. HempMed is targeted at the dispensary market. Joshua Tree is targeted for the mainstream health market.

Currently, MYM Nutraceuticals is constructing three large-scale production facilities in Canada and Australia. These are the Northern Rivers Project; the Weedon Project; and the Laval Project. Upon completion, the total amount of greenhouse growing space will be more than 2.7 million square feet.

The Laval Project facility (Laval, Quebec) is 10,000 sq. ft. It will undergo expansion to 26,000 sq. ft. by 2019. The estimation is that the Laval Project will generate sales of $20 million by 2019.

The Northern Rivers Project (Casino, New South Wales, Australia) is a 1.2 million sq. ft. greenhouse project. The expectation is that the first crop will be planted in Q4 2018. The Northern Rivers Project facility is believed to be the Southern Hemisphere's largest purpose-built greenhouse, designed specifically to produce medical-grade cannabis.

The Weedon Project is in Weedon, Quebec. This Project will include a cannabis museum and a cannabis university for industry training. The Weedon Project has 1.5 million sq. ft. of greenhouse. MYM received approval and started Phase One construction of the Weedon production facility.

Additionality, the Company has its MJT Manufacturing Project (Toronto, Ontario). The 5,000 sq. ft. production facility is a GMP (Good Manufacturing Practice) certified, state-of-the-art extraction lab and production facility dedicated to industrial hemp processing (CBD). MYM Nutraceuticals has acquired an additional 18 percent of CannaCanada and the Weedon, Quebec project bringing its total ownership of the late stage ACMPR applicant, up to 93 percent.

Last week, MYM Nutraceuticals announced that it entered into a partnership with the University of Sherbrooke to study the medicinal and industrial uses of cannabis and hemp. Researchers at the University of Sherbrooke will work with an on-site coordinator to establish partnerships through targeting expertise in different faculties and training centers.

Mr. Rob Gietl, MYM Nutraceuticals’ Chief Executive Officer, said, "The signing of this partnership agreement with University of Sherbrooke furthers our goal to be at the forefront of cannabis plant research and development. Furthermore, I am delighted to see our company associated with a large Quebec university that has an outstanding reputation in research and innovation."

MYM Nutraceuticals, Inc. (MYMMF), closed Friday's trading session at $0.99, down 1.00%, on 144,819 volume with 162 trades. The average volume for the last 60 days is 159,503 and the stock's 52-week low/high is $0.3251/$4.00.

chart

Fortescue Metals Group Limited (FSUMF)

InvestorsHub, YCharts, Equity Clock, OTC Markets, Marketbeat, TradingView, and InvestorVillage reported on Fortescue Metals Group Limited (FSUMF), and today we choose to report on the Company, here at the QualityStocks Daily Newsletter.

Fortescue Metals Group Limited is a global leader in the iron ore industry. The Company has grown to be one of the largest international iron ore producers. At present, it produces 170 million tonnes of iron ore annually. Fortescue Metals Group’s shares trade on the OTC Markets Groups OTCQX. Established in 2003, the Company is based in East Perth, Australia.

Fortescue Metals owns and operates integrated operations covering three mine sites in the Pilbara, the five berth Herb Elliott Port in Port Hedland, and the fastest, heavy haul railway worldwide. The Company now supplies 17 per cent of China’s seaborne iron ore. Fortescue has a fleet of four Fortescue Ore Carriers. Four more are to be delivered in Fiscal Year (FY) 2018.

Fortescue Mining is the first company in Western Australia to control a railway from outside a region of operation. Fortescue Metals wholly owns and operates its purpose designed rail and port facilities. These were built to deliver iron ore from its mines to Port Hedland and on to its customers. The Company’s railway covers 620 kilometers of track.

In addition, it is the first company in the world to use CAT autonomous haulage technology on a commercial scale. Fortescue continues to undertake early stage, low cost exploration on coppergold prospective tenements in South Australia and New South Wales. Moreover, it has assessed high potential, early stage exploration tenements in Ecuador, where it was granted 32 exploration areas.

Fortescue Metals also has its Iron Ore Projects. Its Iron Bridge Project is 100 kilometers south of Port Hedland. This is a JV between Fortescue Metals Group, Taiwan’s Formosa Group, and China’s Baosteel Group, incorporating the world class North Star and Glacier Valley Magnetite ore bodies. Fortescue’s Iron Ore Projects also include the Firetail Replacement Project. Firetail is an important element of the Fortescue Blend product.

Fortescue Metals has expanded autonomous haulage at Chichester Hub. The Chichester Hub in the Chichester Ranges, comprising the Cloudbreak and Christmas Creek mines, has a yearly production capacity of 100mtpa from three Ore Processing Facilities (OPF).

The expansion of its autonomous haul fleet has marked a significant milestone, with the first trucks fitted with Autonomous Haulage Technology (AHS) currently in operation at Christmas Creek. The conversion of about 100 haul trucks at the Chichester Hub will see Fortescue Metals Group become the first iron ore operation in the world to have a fully autonomous fleet.

Additionally, the Company’s operations include The Solomon Hub in the Hamersley Ranges. The Solomon Hub is situated 60 kilometers north of Tom Price and 120 kilometers to the west of Fortescue Metals’ Chichester Hub.

Fortescue Metals Group Limited (FSUMF), closed Friday's trading session at $2.9122, even for the day, on 1 volume with 1 trade. The average volume for the last 60 days is 15,273 and the stock's 52-week low/high is $2.86/$4.79.

chart

GH Capital, Inc. (GHHC)

Penny Picks, OTC Markets, MarketWatch, Barchart, Stockopedia, Morningstar, and InvestorsHub reported on GH Capital, Inc. (GHHC), and we also highlight the Company, here at the QualityStocks Daily Newsletter.

GH Capital, Inc. has developed an online payment gateway (ClickDirectPay) to process online wire transfer transactions for different online merchants, chiefly in Europe. GH Capital is a FinTech holding company and offers a going public process advisory. Formed in 2014, GH Capital has its head office in Miami, Florida. The Company lists OTC Markets’ OTCQB.

GH Capital’s Financial Technology (FinTech) product is ClickDirectPay.com.

Customers using ClickDirectPay can do a bank transfer fast, easily, as well as securely with their personal online banking information. Upon using ClickDirectPay, the merchant receives a real time transaction confirmation pertaining to the successful bank transfer.

GH Capital’s goal is to expand with ClickDirectPay worldwide. To meet this objective, it is working on concepts of Blockchain and Cryptocurrency processing.

Regarding the Company’s Capital Market Advisory Service, it guides and assists international companies from the U.S, Canada, Europe, and Asia to complete the whole going public process from the beginning. GH Capital’s mission is to help small and emerging growth companies to get through the complete IPO (Initial Public Offering) process without difficulties.

GH Capital is also considering acquisitions. The Company stated that 2018 could also be a year of acquiring companies from the payment industry. This could speed up the process to establish ClickDirectPay as a one stop solution for Cryptocurrency processing.

Recently, GH Capital announced that its online payment service subsidiary, ClickDirectPay, announced the launch of ClickDirectPay's Express Coin Payments. This provides merchants the ability to accept many cryptocurrencies into a secure wallet.

In May, GH Capital announced that its online payment service subsidiary, ClickDirectPay expanded its cryptocurrency payment solution offerings to support Monero, Dash, Zcash and Verge. The addition of these coins brings the total support of ClickDirectPay to 8 cryptocurrencies enabling businesses to scale their reach in accepting payments in the world of cryptocurrencies.

ClickDirectPay is introducing new tools for merchants to easily start accepting cryptocurrencies. In June, the Company announced that its online payment service subsidiary, ClickDirectPay rolled-out new tools to its online merchants to be able to more easily and quickly accept cryptocurrency as payment.

GH Capital, Inc. (GHHC), closed Friday's trading session at $0.033, down 5.71%, on 66,500 volume with 9 trades. The average volume for the last 60 days is 15,084 and the stock's 52-week low/high is $0.03/$2.25.

chart

Star Navigation Systems Group Ltd. (SNAVF)

Jet Life Penny Stocks, High Rising Stocks, StreetInsider, Investing News Alerts, MarketWatch, Stockhouse, Marketwired, OTC Markets, The Stock Market Watch, Speculating Stocks, Business Insider, Equities, and PennyStockHub reported on Star Navigation Systems Group Ltd. (SNAVF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Star Navigation Systems Group Ltd. owns the exclusive international license to its proprietary, patented In-flight Safety Monitoring System, STAR-ISMS®. This is the heart of the STAR-A.D.S. ® System. The Company’s M.M.I. Division designs and manufactures high performance, mission critical, flight deck flat panel displays for defense and commercial aviation industries around the world. Star Navigation Systems is based in Toronto, Ontario. The Company lists on the OTCQB.

Star serves commercial airlines, helicopters, and OEMs (original equipment manufacturers), as well as the military aviation search and rescue industries. It provides hardware and software platforms. This includes the STAR-A.D.S. ™, which is real-time global tracking and monitoring systems. In addition, platforms include the STAR-MMI™, which is flat panel and LCD displays and control units.

STAR-MMI™ has developed a wide range of AMLCD flat panel display sizes, with LED Backlights, resolutions, and orientations. These displays are found on aircraft and simulators, from P-3 Orion and C-130 aircraft, to Sikorsky and AgustaWestland helicopters, among others.

Star Navigation Systems developed the STAR-ISMS® In-flight Safety Monitoring System. This is the first system in the world to feature in-flight data monitoring and diagnostics with a real-time, secure connection between aircraft and ground. STAR-ISMS® continuously monitors selected avionics systems on the aircraft from power-on to power-off. It immediately analyzes the data, and transmits selected data and any incident alerts, by way of satellite to the operator.

The Company also offers STAR-ISMS-Medevac. This is a real-time telemedicine for emergency medical evacuation via air transportation. Furthermore, Star offers STAT-T.T.T. This is a satellite flight tracking and voice/text communications system.

Recently, Star Navigation Systems announced that its R&D Department completed development of its new In-Flight System Aided Medical Monitoring system (STAR-ISAMM™) for helicopter MEDEVAC applications. Star announced that its R&D Department has now completed development of its Land System Aided Medical Monitoring system (STAR-LSAMM™) for ground ambulance applications. The ground STAR-LSAMM™ unit is smaller, lighter, and adapted to a ground transportation environment, while the STAR-ISAMM™ is for airborne applications.

This month, Star Navigation Systems confirmed the granting by the US Federal Aviation Administration (FAA) of a Supplementary Type Certificate (STC) for its STAR-A.D.S. ® SSU-G3 tracking and monitoring system. The STC will first be used for a Star customer operating an Airbus A310 in the Middle East. It will also facilitate further worldwide sales on retrofit aircraft.

Star Navigation Systems Group Ltd. (SNAVF), closed Friday's trading session at $0.048, even for the day, on 1,198 volume with 2 trades. The average volume for the last 60 days is 2,222 and the stock's 52-week low/high is $0.031/$0.1326.

chart

AXIM Biotechnologies, Inc. (AXIM)

CFN Media Group, Promotion Stock Secrets, TopPennyStockMovers, and SmallCapVoice reported beforehand on AXIM Biotechnologies, Inc. (AXIM), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.

AXIM Biotechnologies, Inc. is a biotechnology company concentrating on the research, development, and production of cannabis-based pharmaceutical, nutraceutical, and cosmetic products. The Company discovers and brings to market unique solutions by way of research and development (R&D), strategic partnerships, and acquisitions through setting the green standard in the industrial hemp industry. Medical Marijuana, Inc. (MJNA) is a major investor in AXIM. OTCQB-listed, AXIM Biotechnologies is based in New York, New York.

The Company’s focus is on innovative proprietary delivery mechanisms for the introduction of cannabinoids and finding solutions for conditions for which there is currently no effective treatment. AXIM is advancing its patented controlled-release cannabinoid gum in studies encompassing several indications.

AXIM’s flagship CanChew Plus® contains 10mg of cannabidiol (CBD) obtained from industrial hemp plants. The Company also has its CanChew+ 50®, which contains 50 mg of CBD. This product is undergoing clinical trials in patients with IBS (Irritable Bowel Syndrome).

Additionally, AXIM Biotechnologies’ pipeline of Intellectual Property (IP) protected cannabinoid-based products includes MedChew Rx™. This THC/CBD cannabinoid controlled-release chewing gum is to address pain and muscle spasticity in multiple sclerosis (MS) patients. It is the world’s first patented cannabinoid controlled-release chewing gum.

The Company’s IP portfolio now includes two fully issued patents – one patent permitting the use of CBD (cannabidiol) in controlled-release, functional chewing gum, and another patent for chewing gum containing natural and synthetic cannabinoids for the treatment of pain, and 15 patent applications in different stages of approval.

At the end of February 2018, Medical Marijuana, Inc. (MJNA) announced that its major investment company AXIM Biotechnologies successfully executed its first-ever proprietary current good manufacturing practices (cGMP) methodology in the extraction and microencapsulation of cannabinoid molecules for an array of pharmaceutical delivery formats from cGMP-produced medicinal cannabis.

This breakthrough makes AXIM the only Company globally with the ability to harness the proprietary procedure and provide Active Pharmaceutical Ingredients (APIs) of such purity from naturally extracted cGMP sources.

AXIM Biotechnologies, Inc. (AXIM), closed Friday's trading session at $2.24, up 0.90%, on 46,893 volume with 145 trades. The average volume for the last 60 days is 76,217 and the stock's 52-week low/high is $1.70/$10.29.

chart

BioElectronics Corporation (BIEL)

StreetInsider, Barchart, and InvestorsHub reported on BioElectronics Corporation (BIEL), and we highlight the Company as well, here at the QualityStocks Daily Newsletter.

BioElectronics Corporation is a leader in non-invasive electroceuticals and the maker of an industry leading family of disposable, drug-free, pain therapy devices. The Company’s unique medical devices safely and effectively treat chronic and acute pain by way of an innovative mechanism of non-invasive sub-sensory neuromodulation. BioElectronics is based in Frederick, Maryland.

The Company’s products include ActiPatch and RecoveryRx®. ActiPatch® provides advanced long-lasting chronic pain relief using Electromagnetic Pulse Therapy. It is a new and clinically proven drug free technology in the battle against chronic pain.

RecoveryRx® utilizes pulsed electromagnetic therapy to lessen pain and inflammation resulting in accelerated patient recovery and improved comfort. For medical professionals, the RecoveryRx® medical device provides a safe and cost-effective pain management therapy.

BioElectronics products also include Smart Insole™, Allay® Menstrual Pain Relief, and HealFast® Veterinary Pain Relief. The Smart Insole™ comprises Electro-Pulse micro medical devices. These are embedded in comfortable heel gel inserts.

Allay® is an award winning drug-free micro medical device. It utilizes Electromagnetic Pulse Therapy to lessen menstrual pain and discomfort. HealFast® Therapy is a drug-free therapy for horses, cats and dogs. It reduces swelling and pain while it speeds healing of muscle and tendon injuries, sores, as well as incisions.

Recently, BioElectronics announced that the UK’s (United Kingdom’s) government funded public health service, National Health System (NHS), approved the Company’s application to cover and pay for ActiPatch® Musculoskeletal Pain Therapy. The ActiPatch is a drug-free, wearable medical device. It regulates peripheral nerve activity to provide pain relief.

The NHS based its decision considering strong clinical evidence and a health economics study that found that ActiPatch considerably lessened pain and improved quality of life. This is while decreasing overall healthcare costs by 42 percent (58.5 percent reduction in physician appointment costs, 35 percent reduction in prescription medication costs).

Last month, BioElectronics announced the start of a clinical study investigating the efficacy of its RecoveryRx® device for postoperative pain management and recovery following total knee arthroplasty surgery. The clinical study will involve 40 subjects who are already scheduled for a knee replacement. Each subject will be randomly assigned to receive an active device or placebo device. Enrollment into the study has started. The expectation is that the study will be completed in December 2018.

In case studies, RecoveryRx® has shown to be of significant clinical value regarding postoperative pain management and improving long term pain management in subjects undergoing total knee replacement. 

BioElectronics Corporation (BIEL), closed Friday's trading session at $0.0027, up 3.85%, on 19,239,299 volume with 71 trades. The average volume for the last 60 days is 31,021,335 and the stock's 52-week low/high is $0.0005/$0.005.

chart

AEON Global Health Corp. (AGHC)

Amigo Bulls, Stockwatch, Simply Wall St, Zacks, Stockflare, Dividend Investor, Stockhouse, InvestorsHub, YCharts, TradingView, The Street, Stockopedia, Penny Stock Hub, Investing.com, Stock Target Advisor, and Investors Hangout reported on AEON Global Health Corp. (AGHC), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Based in Gainesville, Georgia, AEON Global Health Corp., together with its subsidiaries, provides diverse clinical laboratory testing services in the U.S. It offers diagnostic services in Cancer Genomics, Toxicology, Pharmacogenomics, and Health Technology Applications. Established in 2011, the Company previously went by the name Authentidate Holding Corp. It changed its name to AEON Global Health Corp. this past January.

The name change is part of AEON’s broader rebranding effort. It directly reflects its growth initiatives to enhance its set of service offerings and to introduce its growing variety of services to customers in foreign markets. This includes Latin America and the Middle East.

The Company is the fastest growing clinical lab and healthcare services organization in the United States. It is first in healthcare technology research and development (R&D) where its proprietary methodologies provide expedited and highly accurate urine and oral fluid (saliva) test results.

AEON Clinical Labs services include Cancer Genomics, Pharmacogenomics, Toxicology, and Women’s Health. Health Technologies services include Inscrybe®. This is a secure and simple interface.

Inscrybe® permits physicians, nurses, hospital staff, and external care facilities or health insurers to send, receive, sign, and track healthcare records, supporting documents, patient discharge orders and referrals or lab results and images on the web or through electronic fax instead of transferring paper.

Concerning Telehealth services, the design of the Company’s Telehealth Solutions are to improve outcomes and lessen hospital readmission through helping clinicians closely monitor patients with chronic illnesses such as CHF, COPD and Diabetes.

This past January, AEON Global Health announced that it agreed with Sabal Therapeutics, LLC to be the main laboratory marketer of Naprosyn®,   the branded naproxen oral suspension USP. With this agreement, AEON Global Health will become the exclusive clinical laboratory marketing representative of Sabal. It will market the drug alongside of its industry-leading drug monitoring service.

Therefore, this will provide physicians with an integrated, non-opiate solution for pain management.  Headquartered in Athens, Georgia, Sabal Therapeutics is a pharmaceutical commercialization services company.

Fundamentally, AEON Global Health’s chief business emphasis is offering a “personalized medicine” approach to laboratory testing services. This is to provide customers with actionable medical information.

The Company is an innovator in the genomic testing area. AEON has a wide-ranging menu of genetic tests and a pipeline of additional molecular-based tests in development. AEON Global Health provides post contract customer support services.

AEON Global Health Corp. (AGHC), closed Friday's trading session at $0.67, up 3.08%, on 4,063 volume with 8 trades. The average volume for the last 60 days is 4,744 and the stock's 52-week low/high is $0.40/$1.65.

chart

ZIVO Bioscience, Inc. (ZIVO)

RedChip and Ceocast News reported earlier on ZIVO Bioscience, Inc. (ZIVO), and we report on the Company as well, here at the QualityStocks Daily Newsletter.

ZIVO Bioscience, Inc.’s dedication is to the development and commercialization of nutritional compounds and bioactive molecules derived from its proprietary algal strains. Additionally, the Company engages in the development of natural bioactive compounds for use as dietary supplements and food ingredients, and biologically derived and synthetic candidates for medicinal and pharmaceutical applications in humans and animals, specifically centered on autoimmune and inflammatory response modulation.

Listed on the OTC Markets’ OTCQB, ZIVO Bioscience is based in Keego Harbor, Michigan. The Company’s wholly-owned subsidiary is WellMetris, LLC.

ZIVO Bioscience is re-inventing itself as a licensor of internally developed intellectual property (IP), which includes its proprietary algae cultures, in addition to IP secured via strategic acquisitions. The Company is a biotech/agtech R&D company involved in the commercialization of nutritional and medicinal products derived from proprietary algal strains.

ZIVO Bioscience works to totally harness the beneficial effects of its natural bioactive agents and make them affordable and readily available in a useful and convenient form. The Company has more recently continued to concentrate almost exclusively on dairy cow applications for its proprietary algal biomass, extracts and any high-value bioactive compounds thereof. This is while developing the business case and production scale-up to cultivate and productize the algal biomass.

ZIVO Biosceince’s core IP consists of the algae culture itself, the patented process of producing that culture, and the bioactive compounds or molecules that can be extracted, as well as the application of that culture or extract in supporting health maintenance and longevity.

The Company’s plan is to approach the near-term markets first: animal applications, human food ingredients and human dietary supplements. This is while laying the base for the more complex and longer-term opportunities in the medicinal and pharmaceutical market verticals.

Last week, ZIVO Bioscience announced that Mr. William P. Pfund joined the Company as its new Vice-President of Research & Development. Mr. Pfund will manage overall research goals and compliance initiatives. He will also help transition ZIVO’s ongoing R&D into marketable products and licenses.

Dr. Amy Steffek will continue in her role as Director, Research & Development. She will concentrate mainly on conducting the different tests, studies, and experiments, and manage the data and findings, which populate the ZIVO intellectual property (IP) portfolio. In addition, Dr. Paul Wooley will continue in his role as consulting immunologist.

ZIVO Bioscience, Inc. (ZIVO), closed Friday's trading session at $0.1475, up 9.26%, on 63,793 volume with 14 trades. The average volume for the last 60 days is 99,133 and the stock's 52-week low/high is $0.002/$0.19.

chart

Data Storage Corp. (DTST)

Buzz Stocks, Penny Pick Finders, Penny Picks, PennyStockProphet, Planet Penny Stocks, SecretStockPromo, Stock Onion, EpicVIP Group, TopPennyStockMovers, Real Pennies, Bull Trends, Information Solutions Group, StockMister, Penny Dreamers, Epic Stock Picks, Wolf of Penny Stocks, ActualGains, PennyStockRumors.net, PennyStocks24, PricelessPennyStocks, Stock Twiter, AlphaPennyStock, Investor News Source, RockingPennyStocks, and Stock Guru reported previously on Data Storage Corp. (DTST), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Data Storage Corp. provides cloud-based technology solutions. A Cloud Services Provider, the Company provides hardware, software-as-a-service (SaaS), managed IT (Information Technology) services, installation, and maintenance, focused on compliance, message archiving, analytics, disaster recovery, and business continuity. Data Storage provides its solutions and services through leveraging leading technologies. These include virtualization, cloud computing, as well as cloud storage. Message Logic is a business unit of the Company. Data Storage is based in Garden City, New York.

The Company provides business-to-business (B2B) cloud storage and cloud computing solutions and services in the U.S. and Canada. Data Storage helps organizations internationally in managing and protecting their data, minimizing downtime, and lessening costs while ensuring compliance with regulations. It provides its solutions and services to healthcare, banking and finance, distribution services, manufacturing, construction, education, and government industries.

Data Storage’s solutions include offsite data protection and recovery services, High Availability (HA) replication services, email compliance solutions for e-discovery, continuous data protection, data de-duplication, virtualized system recovery, and telecommunications recovery services. The Company’s Message Logic business unit delivers regulatory compliant email archiving and analytics to enterprises globally.

Message Logic’s MLArchiver provides a solution uniting archiving, records management, eDiscovery, and analytics to deliver a new level of advanced capabilities. Additionally, Data Storage’s Secure Infrastructure & Services centers on providing infrastructure as a service (IAAS). It specializes in power systems, iseries, and AS400 users.

Data Storage has acquired ABC Services and ABC Services II, a 25-year provider of IBM equipment, IAAS, managed and professional services, including the remaining 50 percent ownership of Secure Infrastructure and Services. With this acquisition, Data Storage expands its current solutions. This includes email archival and compliance, Recovery Cloud, Office 365, IBM DR and Cloud Servers. This is while taking advantage of ABC’s network and data security, managed services and equipment.

Recently, Data Storage announced its formation of Nexxis, Inc. This is a new subsidiary of the Company that will concentrate on the development of next-generation voice and data services intended to help companies expedite their communications, increase revenue and lessen costs.

Mr. John Camello will serve as President of Nexxis. Mr. Camello is a veteran telecommunications entrepreneur and executive. He has considerable experience in providing nationwide telecommunication services. Mr. Camello said, “I’m excited to lead this new venture.  We intend to offer standalone voice, internet and transport services, as well as complete next-generation voice and data solutions that will incorporate auto failover with the goal of delivering unmatched reliability and value.”

Data Storage Corp. (DTST), closed Friday's trading session at $0.1949, up 3.13%, on 1,550 volume with 3 trades. The average volume for the last 60 days is 46,851 and the stock's 52-week low/high is $0.068/$1.00.

chart

The QualityStocks Company Corner

The Green Organic Dutchman (TSX: TGOD) (OTC: TGODF)

The QualityStocks Daily Newsletter would like to spotlight The Green Organic Dutchman (OTC: TGODF).

The Flowr Corp. (“FLOWR”), a Canadian licensed producer that focuses primarily on premium flower production, was recently highlighted in an article on TheStreet.com titled, “Will Investors Be Ready to Digest All the New Cannabis Stocks?” authored by Debra Borchardt. The article shines a light on the array of cannabis-related businesses that have recently filed and completed initial public offerings (“IPOs”). One such company is The Green Organic Dutchman Holdings Ltd. (TSX: TGOD) (OTCQX: TGODF). To view the full article, visit: http://nnw.fm/a8avJ.

The Green Organic Dutchman (TSX: TGOD) (OTCQX: TGODF), whose principal location is in Hamilton, Ontario, produces farm grown, organic, pesticide-free medical cannabis in small batches using all natural, organic craft growing principles. TGOD is licensed under the Access to Cannabis for Medical Purposes Regulations (ACMPR) to cultivate medical cannabis. The company carries out its principal activities producing cannabis pursuant to the provisions of the ACMPR and the Controlled Drugs and Substances Act (Canada).

Committed to becoming the global leader in delivering organic cannabis solutions that enhance people’s lives, TGOD consistently adheres to the highest levels of excellence. Its world-class management team includes a proven group of leaders with outstanding executive and operational experience specific to consumer packaged goods, consumer products, cannabis and finance industries.

TGOD is positioned as one of the highest quality and most cost efficient cannabis producers in Canada by leveraging innovative technology and low-cost power solutions. It holds one of the largest land packages under a single ACMPR license in Canada, providing future cannabis Agri-park style development and opportunities for joint ventures, licensing and distribution partners. Its industry leading alliance partners include Eaton, Ledcor Group and Hamilton Utilities Corp.

Eaton is the second largest power management company in the world and promises to supply innovative and cost effective power solutions to meet TGOD’s growing demands. Construction management is supplied by Ledcor, Canada’s second largest multidisciplinary construction company and a pioneer in the Green Building Industry. An alliance with Hamilton Utilities Corp allows TGOD to reduce its power costs from $0.13 per kWh to less than $0.05 per kWh. Greenhouse design is provided by Larssen Greenhouse, whose 25-plus years of experience in building some of the most modern and sophisticated greenhouses in the industry will provide TGOD with state of the art, climate-controlled hybrid greenhouse solutions.

Canada is quickly becoming a hub for cannabis investors with over $1.3 billion raised by Canadian companies to date. There are 58 licensed producers to service a population of 36 million and only two organic producers. TGOD, which holds licenses in Ontario and Quebec, is strategically located in both provinces that together claim 22 million Canadians as residents. Another estimated 57 million people live next door in six U.S. bordering states.

The Canadian cannabis market currently has a massive supply demand gap, which makes TGOD’s expansion plans even more important to investors. These plans include a combined build-out capacity of 970,000 square feet, allowing TGOD to produce 116,000 kg annually of organic cannabis. Upon completion, Phase One in Hamilton, Ontario, which is fully funded, will provide 150,000 square feet of growing capacity capable of producing up to 14,000 kg of cannabis or $112 million in revenue at $8 a gram.

The company’s Quebec expansion will be constructed on a recently secured 75-acre property near Montreal. This new property has a planned expansion of 820,000 square feet capable of producing 102,000 kg of organic cannabis. The first phase of this expansion is underway and construction is expected to be completed by the end of 2018. Quebec’s first phase will consist of 220,000 square feet capable of producing 22,000 kg of cannabis. Two additional expansion phases will add 250,000 square feet (26,000 kg of cannabis) and 350,000 square feet (54,000 kg of cannabis). Power costs remain exceptionally low for both facilities with access to all other needed utilities available and close by.

TGOD also plans to gain a share of the burgeoning cannabis oils market which by Q1 2017 accounted for 49 percent of all cannabis sold in Canada under the ACMPR, up from only 27% in Q2 2016. TGOD has ordered a purpose-built extraction laboratory with an estimated commission in Q4 of 2017. This is a commercial-scale CO2 extraction unit capable of processing up to 12,000 kg of raw material per year and producing approximately $170 million worth of organic cannabis oils. Raw cannabis oil provides a significant downstream manufacturing opportunity into several potential recreational market verticals including edibles, beverages, topicals and concentrates.

Data from the Canadian ACMPR Market Trends report indicates a rising number of consumers will continue to seek out healthier, less conspicuous ways to consume cannabis, ensuring sales of organic cannabis oil products remain brisk. Organic cannabis products demand a significant premium compared to non-organic products and the demand keeps growing.

Plans to take the company public are underway with an initial public offering (IPO) slated for January 2018. In November, the company raised $13 million in equity financing and in March closed a $27 million non-brokered private placement. Another $20 million is currently being raised before the IPO in January, which will be utilized for expansion plans.

TGOD is uniquely positioned between the medical and recreational cannabis industry since Canada is scheduled to legalize cannabis for all adults in mid-2018. As of August 2017, TGOD has 2,400 shareholders. Established in 2012, TGOD’s motto, “Making Life Better,” can be seen in its strategic partnerships, top quality management team, and dedication to organic farming and principles.

To learn more about the company and how to invest, contact TGOD directly at financing@tgod.ca

The Green Organic Dutchman (OTC: TGODF), closed the day's trading session at $4.3389, up 1.38%, on 196,454 volume with 571 trades. The average volume for the last 60 days is 209,364 and the stock's 52-week low/high is $2.784/$7.565.

Recent News

chart

Youngevity International, Inc. (NASDAQ: YGYI)

The QualityStocks Daily Newsletter would like to spotlight Youngevity International, Inc. (YGYI).

Leading omni-direct lifestyle company Youngevity International, Inc. (NASDAQ: YGYI) yesterday highlighted its new Hemp FX™ product line, which was introduced at the company’s 2018 convention in San Diego, California. To view the full press release, visit: http://cnw.fm/6AcfR.

Youngevity International, Inc. (NASDAQ: YGYI) is a leading omni-direct lifestyle company offering a hybrid of the direct selling business model that includes e-commerce and the power of social selling. Among the Top 100 Global Direct Selling Companies, Youngevity offers products from the six top selling retail categories: health/nutrition, home/family, food/beverage (including coffee), spa/beauty, apparel/jewelry, and a range of innovative services. Created through the 2011 merger of Youngevity Essential Life Sciences with Javalution® Coffee Company, today’s Youngevity International Inc. is a virtual worldwide Main Street of products and services under one corporate entity that supports a healthy and empowered lifestyle.

Youngevity International is dedicated to improving lifestyles through the universal desires of vibrant health and flourishing economics. Catering to health-conscious consumers, Youngevity believes that combining the best of the direct selling industry with the fundamentals and capabilities of a traditional business model will maximize shareholder value. The company’s Nutritional, Lifestyle and Telecommunications products and services are distributed through a global network of Preferred Customers and Distributors.

Youngevity’s wholly owned CLR Roasters LLC business line offers quality branded and private label coffee to retail stores, office coffee services, hospitality, food services, distributors, convenience, petrol stores and vending businesses. Today, CLR Roasters is the largest coffee provider for cruise lines in North America and the second largest roaster in the state of Florida. Producing a consistent premium product with superior taste, CLR Roasters has earned numerous certifications that demonstrate the company’s commitment to the craft of providing the highest quality coffee products using the best practice standards available.

Youngevity, operating in the direct-selling channel, is rapidly expanding its product and distributor base through acquisitions and mergers under an innovative concept called “the Network Cloud” that provides other direct selling companies with a home base. The company’s YoungevityGO2 mobile distributor app, a new technology-driven web platform supporting expansion of global e-commerce and social selling platforms, is available on Google Play and the App Store. In addition to the Network Cloud concept, Youngevity International owns CLR Coffee Roasters which operates a traditional coffee roasting business offering a JavaFit® gourmet product line that vertically integrates with Youngevity and its growing network of direct marketers.

Youngevity International offers more than 1,000 high quality, technologically advanced products under the following categories:

  • Health and Nutrition
  • Home and Family
  • Food and Beverage
  • Spa and Beauty
  • Fashion
  • Essential Oils
  • Photo and scrapbooking
  • Services for Home and Business

Youngevity International Inc. has compiled a best-in-class management team with a strong track record of success in private and public companies. Steve Wallach, CEO, has nearly two decades of sales and network marketing experience and has successfully guided Youngevity International Inc. to become an international, publicly-traded direct marketing company positioned for worldwide growth. Dave Briskie, president and CFO, has shepherded the company’s development into a fully vertical coffee roasting and distribution company that owns the direct marketing brand JavaFit® and the retail brand, Café La Rica.

Youngevity has also attracted a stunning group of Brand Evangelists who endorse its products. Among these are actress, author and well-known health and wellness activist Marilu Henner; former NBA basket player, Mike “Stinger” Glenn; former NFL wide receiver Drew Pearson; “Greatest Natural Bodybuilder in the World” Gene Nelson; and WNBA champion, Olympic gold medalist Delisha Jones.

Youngevity International, Inc. (NASDAQ: YGYI), closed the day's trading session at $3.57, off by 7.73%, on 38,308 volume with 190 trades. The average volume for the last 60 days is 17,952 and the stock's 52-week low/high is $3.1674/$6.75.

Recent News

chart

ChineseInvestors.com (OTCQB: CIIX)

The QualityStocks Daily Newsletter would like to spotlight ChineseInvestors.com (CIIX).

ChineseInvestors.com, Inc. (OTCQB: CIIX) CEO Warren Wang discussed details of their recently filed 10k this week on MoneyTV with Donald Baillargeon. The television program can also be viewed online immediately at www.moneytv.net. Also today, NetworkNewsWire released a report on the company detailing how CIIX intends to spin off its cannabis-related products into its wholly-owned ChineseHempOil.com, Inc. subsidiary. To view the full article, visit: http://nnw.fm/PQb1b.

Founded in 1999, ChineseInvestors.com (OTCQB: CIIX) has become a leading financial information website for Chinese-speaking investors in the United States and China. Recognizing unprecedented opportunities in the U.S. cannabis industry, CIIX is also laying the groundwork to capitalize on growing demand for cannabidiol (CBD)-based nutrition and health products.

Through its primary website, www.ChineseInvestors.com, CIIX offers a variety of investor education products and services, including real-time market commentary, analysis and educational related services in Chinese language character sets; consultative services to smaller private companies considering becoming a public company; and advertising and public relations related support services.

At the center of this initiative is the ChineseInvestors Method, a unique integration of a disciplined investing process, web-based tools, personalized instructions and support. Using this strategy, CIIX provides reliable market information to help investors make informed investment decisions and meet their individualized financial goals.

CIIX is also leveraging its financial expertise to enter into the burgeoning CBD industry, which within a few years has grown from a relatively invisible sector to a billowing market expected to reach $2.1 billion in consumer sales by 2020.

The increasing demand for CBD-based products is a catalyst for innovative business endeavors. To this accord, CIIX has established a three-year development plan to capitalize on the convergence of CBD and the nutrition and health products market in mainland China, where the benefits of CBD oil have not been widely recognized.

Under a wholesale agreement with a reputable CBD health brand, CIIX is launching the world’s first online CBD health products store published in the Chinese language. The site, www.ChineseCBDoil.com, caters to a growing number of Chinese people awakening to the numerous health benefits of CBD oil for treatment of a variety of conditions such as anxiety, stress, poor sleep, Alzheimer’s disease, and more. CIIX expects to launch this website at the end of January 2017, and plans to sell CBD-infused products via online and in-store.

In conjunction, CIIX’s cannabis-focused “Yelp”-style mobile app is in development as a platform for Chinese people to review and discuss various cannabis products. The app will be the first marijuana social media mobile app designed for Chinese-speaking customers worldwide.

ChineseInvestors.com (CIIX), closed the day's trading session at $0.56, up 5.66%, on 195,258 volume with 105 trades. The average volume for the last 60 days is 226,550 and the stock's 52-week low/high is $0.365/$1.58.

Recent News

chart

The Flowr Corporation

The QualityStocks Daily Newsletter would like to spotlight The Flowr Corporation.

The Flowr Corp. (“FLOWR”), a Canadian licensed producer that focuses primarily on premium flower production, was recently highlighted in an article on TheStreet.com titled, “Will Investors Be Ready to Digest All the New Cannabis Stocks?” authored by Debra Borchardt. To view the full article, visit http://ibn.fm/nwNsx.

The Flowr Corporation, a Health Canada Licensed Producer (LP) of cannabis under the Access to Cannabis for Medical Purposes Regulations (ACMPR), is an emerging Canadian cannabis leader founded by Medreleaf co-founder Tom Flow and a team of industry pioneers, successful start-up executives and top industry scientists. Flowr’s purpose-built cultivation facilities may be the most advanced in the industry, consistently generating high crop yields, delivering premium and ultra-premium cannabis products, and maximizing return on investment. The company also may be an R&D leader as it was selected by the Hawthorne Gardening Division of The Scotts Miracle-Gro Company as its exclusive Canadian cannabis R&D partner.

Flowr’s flagship facility, an 84,000-square-foot campus on seven acres in Kelowna, British Columbia, is engineered to grow premium cannabis in rooms that meet pharmaceutical industry production standards for cleanliness. This, along with exacting protocols designed by the Flowr team, enables Flowr to grow cannabis that meets Health Canada’s stringent standards without treating it with the taste- and smell-killing gamma irradiation that most other producers have to use to clean their product. Irradiating the plant – a process similar to pasteurizing food – impairs many of the important terpenes that provide the positive effects, flavors and scents of cannabis while strengthening unpleasant terpenes. Flowr’s products may deliver a better user experience, thus commanding premium prices.

Flowr’s cultivation facilities, built with proprietary, patent-pending systems, are designed to deliver yields targeted at 450 grams per square foot by the end of 2022, which is three times more efficient than the industry average of approximately 150 grams per square foot. By optimizing yield, the Company may produce significantly more cannabis flower on a smaller footprint than other producers, thus generating far high revenue per square foot and keeping costs much lower, leading to higher margins. The Kelowna facility is presently 20 percent operational with the remaining 80 percent slated to come online by early 2019. It is expected to produce up to 14,000 kg of premium, non-irradiated cannabis flower in 2019. With further enhanced yields and planned expansion of production facilities on the campus, Flowr will reach a total capacity of 60,000 kg annually in 2022.

Leading Flowr’s cultivation program is industry pioneer, company co-founder and Flowr president Tom Flow. Flow is widely recognized for his cannabis thought leadership and expertise building and operating cannabis cultivation facilities. Flow also co-founded MedReleaf and designed, built and set up SOPs for their flagship Marcum cultivation facility. Marcum has continued to be perhaps the most productive facility in the country prior to the Flowr flagship facility. Long one of Canada’s most efficient and profitable LPs, MedReleaf was acquired by Aurora for approximately C$3 billion. Flow and his team have designed and built a total of 17 cultivation facilities and secured three producer’s licenses under various Canadian regulatory regimes.

In March 2018, Flowr and the Hawthorne Gardening Division of The Scotts Miracle-Gro Company – a world leader in lawn and garden products – announced an exclusive strategic R&D alliance. After evaluating numerous Canadian LPs, Hawthorne chose to partner with Flowr based on the experience and expertise of the company’s cultivation and R&D teams and the company’s advanced growing capabilities.

Hawthorne will fund the construction of a 50,000-square-foot R&D facility that is integrated into Flowr’s Kelowna campus. This facility is North America’s first dedicated cannabis R&D facility focused on advancing cultivation techniques and systems. The facility will support researchers from both organizations and combine laboratories, indoor and greenhouse grow suites, training areas and genetics breeding areas in a single building. It is expected to open in early 2019. In addition to helping Flowr maintain its competitive advantage in cultivation, the company’s R&D program will keep it on the cutting edge of cannabis innovation.

Flowr is entering the market with three different brands to meet the growing demand for premium, non-irradiated cannabis in the medicinal and adult use markets:

  • FlowrRx, featuring premium quality medicinal cannabis that enables patients to live better, fuller lives. A dedicated Client Services team will provide patients with personalized support while an R&D team develops innovative flower strains and premium products targeted to specific conditions. Patient well-being is considered at every stage of the process – from genetic selection to harvest, trimming and curing techniques. FlowrRx and its team of passionate scientists and leading cultivation specialists are dedicated to advancing the scientific understanding of cannabis.
  • Flowr is the company’s premium recreational adult-use brand featuring an active, West Coast-inspired lifestyle for the cannabis connoisseur and enthusiast market. Through the continuous innovation of procedures and practices, Flowr’s talented team of experts is crafting premium products that deliver unparalleled experiences.
  • Ace Valley, an exclusive partnership with top-selling Ontario craft beer company Ace Hill, will bring Flowr’s premium product to the millennial and casual adult-use markets under the Ace Valley brand.

Flowr recently signed a Memorandum of Understanding with the British Columbia Liquor Distribution Branch, the province’s sole legal wholesaler of non-medical cannabis, to supply premium and ultra-premium flower to the province’s retail outlets. The company has agreements with several major medical distributors and is in discussions about retail distribution with additional provinces where it believes it can obtain prices commensurate with the quality of the Flowr products. The company is also evaluating other market opportunities including export.

Flowr is poised to become the pre-eminent indoor premium cannabis grower in Canada and one of the country’s top five LPs. The company’s focus on yield, quality and price point and its team’s ability to grow at scale should drive high margins, significant growth and strong return on investment.

Recent News

Earth Science Tech, Inc. (OTC: ETST)

The QualityStocks Daily Newsletter would like to spotlight Earth Science Tech, Inc. (ETST).

Biotechnology company Earth Science Tech (OTC: ETST) is firm on its mission to be a major provider of premier CBD products, and is working toward that goal. To view the full article, visit: http://nnw.fm/9qL5C.

Earth Science Tech, Inc. (OTC: ETST) is an innovative biotechnology company operating in the fields of hemp cannabinoid (CBD), nutraceutical, pharmaceutical and medical device research and development. Earth Science Tech offers the highest purity and quality, full-spectrum, high-grade hemp CBD (cannabidiol) oil on the market. Made using the supercritical CO2 liquid extraction process, the company’s CBD oil is 100 percent natural and organic. Earth Science Tech has partnered with the University of Central Oklahoma and DV Biologics Laboratory to conduct research and development projects that scientifically support and advance the healthcare benefits of its high-grade hemp CBD oil.

Earth Science Tech Inc. currently has three wholly owned subsidiaries focused on developing its role as a world leader in the CBD space and expanding its work in the pharmaceutical and medical device sectors. These subsidiaries include:

  • Earth Science Pharma, Inc., which is committed to development of low cost, noninvasive diagnostic tools, medical devices, testing processes and vaccines for sexually transmitted infections and/or diseases. Earth Science Pharmaceutical CEO and chief science officer Michel Aubé is leading the company’s research and development efforts. The company’s first medical device, MSN-2, is a home kit designed for the detection of STIs, such as chlamydia, from a self-obtained gynecological specimen. Earth Science Pharma is working to develop and bring to market medical devices and vaccines that meet the specific needs of women.
  • Cannabis Therapeutics, Inc. (“CTI”), which is poised to take a leadership role in the development of new, leading-edge, cannabinoid-based pharmaceutical and nutraceutical products. CTI is invested in research and development to explore and harness the medicinal power of cannabidiol. The company holds a provisional application patent for a CBD product that is focused on developing treatments for breast and ovarian cancers.
  • KannaBidioiD (“KBD”) provides a wide variety of products geared toward the recreational space of cannabis. KBD’s unique Kanna and CBD formulation is sold and distributed in CBD-infused edibles and vapes/e-liquids products. Kanna and CBD synergistically enhance one another, providing optimal relaxation, an uplifting sensation, enhanced focus and the added benefit of assisting with nicotine reduction therapy.

Earth Science Tech celebrated a significant, developmental year during 2017 by sharing its achievements in a condensed end-of-year report. Among the report’s highlights are the implementation of a development plan for the coming three years, which includes expanding into Canada and opening new manufacturing and shipping facilities. Of particular interest is the acquisition of Canna Inno Laboratories Inc., a company headquartered in Montreal, Quebec, Canada, which gives Earth Science Tech access to Canadian government grants offered to innovators in the pharmaceutical industry. ETST has also launched development of proprietary prophylactic therapies utilizing cannabidiol (CBD) to treat various forms of breast cancer.

In October 2017, ETST announced it is cooperating with the Clinique SIDA Amité (AIDS Friendship Clinic) for a mini-clinical trial, the last trial needed before the MSN-2 device, designed for the detection of STIs, enters molecular diagnostic trials. And in November 2017, the company began pre-launch human trials on a new CBD formula to fight against the U.S. opioid epidemic. The new formula, expected to decrease cravings and the negative effects of withdrawal in addicts, is based on industrial hemp CBD mixed with a known natural ingredient proven to help increase dopamine levels. ETST’s medical devices will first be launched in Vietnam, Djibouti and Morocco while the company awaits regulatory permission to enter the North American market.

The company expects to up-list to the OTCQB in early 2018, which management believes will attract well-funded institutional investors and pave the way to becoming the next billion-dollar-in-capitalization company on the OTC markets. Other highlights include completion of the company’s Scientific Advisory Council with a team of recognized scientists, the launching of several CBD-infused edible products and entry into the medical devices market through collaborative partnerships.

Earth Science Tech has signed a collaborate agreement with Laboratories BNK Canada, a private laboratory that will conduct the clinical studies necessary for MSN-2 medical device-related services to meet regulatory requirements. ETST has confirmed the MSN-2 device’s ability to detect chlamydia, and is working to validate similar results for gonorrhea, both highly infectious diseases that often have permanent consequences for patients. ETST will also add testing for trichomoniasis and a complete body fluid panel to detect the different serotypes of the human papillomavirus (HPV) that causes cervical cancer. These additions will help the company create sales opportunities in the global market for diagnostic testing of STDs that Transparency Market Research has indicated will grow to $108 billion by 2019.

Cannabis Therapeutics is in the development stage of two cannabinoid-based pharmaceutical drugs and three cannabinoid-based nutraceutical products targeting a variety of ailments such as anxiety, depression, triple negative breast cancer, and fatty liver disease, among others. Research into the benefits of the non-psychoactive cannabinoid molecules found in the cannabis plant is supported by ETST’s International Application for Provisional Patent titled “Cannabidiol Compositions Including Mixtures and Uses Thereof,” which was filed on October 8, 2015. Cannabis Thera’s R&D efforts are concentrated on developing CBD-based drugs and nutraceutical products and in working to integrate the CBD molecule with existing generic drug molecules to create more efficient medications with fewer and less severe side effects. A report in Hemp Business Journal predicts the CBD consumer market will grow to $2.1 billion by 2020, while other industry experts expect an increase to almost $3 billion by 2021. A recent report by Statista projects the U.S. consumer market for cannabinoid-based pharmaceuticals could reach $50 billion by the year 2029.

The management team at Earth Science Tech brings decades of invaluable experience to the nutraceutical, dietary supplement field as well as the life sciences sectors. Nickolas S. Tabraue, who serves as the president, director and chief operating officer, is an industry veteran with extensive knowledge of supplements, retail management, customer service and sales expertise. He is joined by CEO and CSO Dr. Michel Aubé, a microbiologist whose scientific research in sexually transmitted infections, cancer and stem cell biology has been widely published in several prestigious medical journals. Sergio Castillo, chief marketing officer, and Gabriel Aviles, chief sales officer, bring a wealth of marketing and sales experience to Earth Science Tech, which is complemented by Issa El-Cheikh, Ph.D., and his 25 years in the international finance, accounting, planning and execution of large scale transactions in the public and private sectors.

Earth Science Tech’s products include CBD, a natural constituent of hemp oil derived from hemp stalk and seed. EST offers CBD in the form of vitamins, minerals, herbs, botanicals, personal care products, homeopathies, functional foods and other products delivered in such forms as capsules, tablets, soft gels, chewables, liquids, creams, sprays, powders and whole herbs. Earth Science products can be found at retail stores throughout the United States and are available for purchase through the internet.

Earth Science Tech, Inc. (ETST), closed the day's trading session at $0.80, up 5.26%, on 27,914 volume with 27 trades. The average volume for the last 60 days is 11,357 and the stock's 52-week low/high is $0.324/$1.62.

Recent News

chart

SinglePoint, Inc. (OTCQB: SING)

The QualityStocks Daily Newsletter would like to spotlight SinglePoint, Inc. (SING).

Singlepoint, Inc. (OTCQB: SING) President Wil Ralston said their Stakehaul sports betting app is geared up for the NFL season this week on MoneyTV with Donald Baillargeon. Also today, NetworkNewsWire released a report on the company detailing the aforementioned interview.  To view the full interview, visit: http://nnw.fm/YO2yB. To view the full press release, visit: http://nnw.fm/U29bv.

SinglePoint, Inc. (OTCQB: SING) is a diversified holding company with operations in multiple industries and verticals including two high-performing market sectors: legal cannabis and cryptocurrencies. SinglePoint has grown from a full-service mobile technology provider to a recognizable brand with a diverse portfolio of undervalued subsidiaries with multiple revenue streams.

SinglePoint is researching opportunities where it can be an active participant by influencing the strategy and direction of high-potential companies whose verified assets offer attractive possibilities for shareholders. The company is guided by a visionary leadership team with extensive experience in technology, engineering, marketing and raising capital.

SinglePoint is bullish on the cannabis industry, bitcoin and blockchain technologies, which is evident in its recent acquisitions and joint-venture announcements. Recent SinglePoint key highlights include:

  • A joint venture with Smart Cannabis Corporation (OTC: SCNA) to license and market Smart Cannabis’ SMART APP. SMART APP enables cannabis growers to measure all aspects of cultivation, from soil nutrient levels to watering cycles and carbon dioxide content in the air. SMART APP will integrate SinglePoint’s bitcoin payment solution to enable growers to process safer and more secure transactions.
  • A joint venture with Global Payout (OTC: GOHE) will build on existing financial technology solutions developed by SinglePoint and Global Payout’s subsidiary MoneyTrac Technology, Inc., to fully optimize the delivery of mobile payment applications for domestic and international organizations.
  • A joint venture with AppSwarm (OTC: SWRM) to start development on a proprietary delivery application that will enable licensed cannabis delivery services and licensed dispensaries to safely make in-home cannabis deliveries.
  • Signed original “Shark Tank” member Kevin Harrington as company spokesman for an innovative, compatible virtual wallet to store any type of cryptocurrency. Harrington recently finished shooting a new national ad campaign featuring SinglePoint and the virtual wallet’s secure method of storing cryptocurrencies.
  • Entered into a letter of intent to acquire 100 percent of Bitcoin Beyond, a premier platform that enables merchants to accept bitcoin payments using existing web-enabled point-of-sale devices.
  • Through SING subsidiary, SingleSeed, the company will soon offer a proprietary cryptocurrency solution that links both cannabis merchants and consumers who seek to take advantage of bitcoin-powered transactions using debit and credit cards. In addition to making bitcoin-backed card purchases possible, the solution enables cannabis dispensaries to digitally track and manage their product inventories, performing tasks like uploading product data, photos and descriptions. The system deducts items automatically from a dispensary’s product listings when a purchase is made. While this fully KYC-AML compliant point-of-sale platform can be utilized for any other retail setting, it will fill a critical need in the underbanked cannabis industry as it continues to seek non-cash payment solutions outside of traditional banking circles.

SinglePoint CEO and founder Greg Lambrecht leads the company in its mission to capture opportunities through an aggressive expansion strategy across a broad range of assets. Lambrecht oversees all company operations including investor relations, leadership of the board of directors, and daily business activities. As the founder of PCI, a leading consumer product distribution company, Lambrecht negotiated agreements with the nation’s largest retail outlets and led PCI through a NASDAQ listed IPO, raising $10 million.

Eric Lofdahl, SinglePoint’s chief technology officer, has more than 20 years of experience in the technology sector including positions in software development, program management, complex system integration and engineering process definition. Prior to SinglePoint, Lofdahl worked at the Boeing Company where he led a team that successfully developed advanced wireless and satellite data products based on commercial technology for the U.S. Air Force.

SinglePoint President Wil Ralston is well known for his successful track record of building and maintaining great relationships with clients. Ralston graduated cum laude from the WP Carey School of Business at Arizona State University with a degree in Global Agribusiness and a specialization in Professional Golf Management. He is currently recognized by the Professional Golfers Association of America (PGA) as a Class A Professional.

SinglePoint, Inc. (SING), closed the day's trading session at $0.031, up 1.11%, on 3,595,796 volume with 151 trades. The average volume for the last 60 days is 5,991,654 and the stock's 52-week low/high is $0.0235/$0.133.

Recent News

chart

Sunniva, Inc. (CSE: SNN) (OTCQX: SNNVF)

The QualityStocks Daily Newsletter would like to spotlight Sunniva, Inc. (SNNVF).

Sunniva (CSE: SNN) (OTCQX: SNNVF) was recently covered in a publication by Beacon Securities Limited that argued that Sunniva is significantly undervalued. To view the full article, visit: http://nnw.fm/5dqdF.

Sunniva, Inc. (CSE: SNN) (OTCQX: SNNVF) is a vertically integrated medical cannabis company operating in the world’s two largest cannabis markets – Canada and California – committed to delivering safe, consistent, high-quality products and services. Sunniva operates through its wholly owned subsidiaries: Sunniva Medical Inc., CP Logistics, LLC, Natural Health Service Ltd., and Full-Scale Distributors, LLC. Sunniva’s vision is to become the lowest cost, highest quality cannabis producer in the markets it serves by building large scale purpose-built cGMP-compliant greenhouses, offering best quality assurance with cannabis products free from pesticides, providing better patient and doctor access to cannabis education, and sourcing better therapeutic delivery devices.

The company is establishing sophisticated distribution channels, including Sunniva’s ownership of Natural Health Services cannabis clinics in Canada with over 95,000 active patients, to purchase the significant quantities of high quality Sunniva-branded and Sunniva private-labeled cannabis products.

Sunniva is an ancient English name which means, “Gift of the Sun.” Sunniva’s team of horticulturists, scientists and engineers is helping to set best practices for the industry, believing that sun-grown, solar-powered cultivation is the most sustainable and cost-effective way to grow high-quality, premium cannabis.

The Sunniva Family includes:

CP Logistics, LLC

Through its subsidiary, CP Logistics LLC, Sunniva is developing Sunniva Campus, a state-of-the-art, purpose-built greenhouse facility in Cathedral City, California. This modern purpose-built, agri-technology greenhouse will adhere to the Current Good Manufacturing Practice (cGMP) regulations that assure proper design, monitoring and control of manufacturing processes and facilities.

Phase 1 of the project includes a fully funded 325,000 square foot greenhouse capable of producing 60,000 kg per year of dry cannabis at capacity with operations commencing Q3 2018. Approximately 30 percent of initial total production will be converted into oils and extracts. Phase 2 is expected to increase the greenhouse by 165,000 square feet and grow production by about 40,000 kg per year.

These uniquely sealed greenhouses are designed to deploy custom, automation assembly line cultivation processes at a large scale. Energy consumption will be reduced while utilizing the energy of the sun and microclimatic controls to provide precise growing conditions. The greenhouse will recirculate air for more efficient climate control, and the company’s Integrated Pest Management System is designed to ensure every plant grown is certified clean and free of all contaminants and pesticides.

Sunniva Medical Inc.

Sunniva Medical Inc. is designing and preparing to break ground on the Sunniva Canada Campus encompassing 700,000 square feet of purpose-built cGMP greenhouse facilities in the Okanagan Valley, British Columbia. The total campus is expected to produce 100,000 kg of premium medical cannabis a year plus additional trim used for extraction. This facility will produce pesticide-free products and will convert trim to extracted products such as cannabis oil that can be used for drug delivery formats such as capsules, dissolvable strips, vaporization cartridges, tinctures and creams.

Sunniva and Canopy Growth Corporation (“Canopy Growth”) recently announced a large take or pay supply agreement. Under the terms of the agreement, Canopy Growth will purchase up to 45,000 kilograms of dried cannabis annually commencing Q1 2019, which includes the distribution of Sunniva branded products. Sunniva Medical is a late-stage applicant under Canada’s ACMPR and is in the final review stage of the process.

Natural Health Services Ltd.

Natural Health Services (“NHS”) owns and operates a network of eight medical clinics in Canada specializing in medical cannabis under the Access to Cannabis for Medical Purposes Regulations (“ACMPR”). NHS connects licensed producers to their 21 physicians and patients with its proprietary SPARK software which utilizes a software-as-a-service revenue model. To date, there are 27 integrated licensed producers utilizing the SPARK software.

In-house physicians specializing in the endocannabinoid system provide expert consultation, education and recommendations for targeted phytoceutical remedies and wellness plans to improve the quality of life for all patients. NHS enjoys a long-term relationship with patients due to the quality of its physician-patient experience. A rapidly expanding NHS cannabis clinic network serves 94,000 active patients in Canada. NHS has also initiated a pilot program with a national pharmacy chain to aggregate more patients.

Full-Scale Distributors, LLC

Full-Scale Distributors, LLC is an industry leading provider of custom, private-label vaporizers through its brand, Vapor Connoisseur. The company currently serves the needs of over 80 top brands in the North American marketplace. Vapor Connoisseur is recognized for its high quality and innovative therapeutic delivery devices. Products are tailored to client needs, ensuring both safety and reliability.

Sunniva’s highly experienced management team is building partnerships with leading scientists, universities and clinical trial groups to deliver proprietary cannabis formulations to a broad spectrum of health ailments and conditions. These global partners require cGMP-certified facilities for the processing and manufacturing of cannabis products. Sunniva is committed to providing safe, pesticide-free, high quality, reproducible cannabis medicines.

Leading Sunniva is co-founder, chairman and CEO Dr. Anthony (Tony) Holler. He is the former CEO and founder of ID Biomedical, which was acquired in 2005 for $1.7 billion by GlaxoSmithKline. He is also the former chairman of Corriente Resources Inc., which was sold for approximately $700 million to CRCC-Tongguan Investment Co. Holler is currently chairman of CRH Medical Corporation, a public company trading on the TSX and NYSE. His expertise includes strategic planning, mergers and acquisitions and financing with a singular focus on increasing shareholder value.

Holler is joined by co-founder Leith Pedersen, who serves as president of Sunniva. Pedersen is the former owner and CEO of Vida Wealth Management Bahamas and was a former investment advisor at Canaccord Wealth Management. He is a former partner and director at JF Mackie and Company, an independent brokerage firm in Calgary, Alberta, that managed capital in excess of $2 billion for high net worth clients. Pedersen’s expertise is in corporate strategy, financing and mergers and acquisitions.

Sunniva, Inc. (SNNVF), closed the day's trading session at $5.11, up 0.34%, on 103,511 volume with 196 trades. The average volume for the last 60 days is 52,375 and the stock's 52-week low/high is $3.61/$16.00.

Recent News

chart

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP)

The QualityStocks Daily Newsletter would like to spotlight Lexaria Bioscience Corp. (LXRP).

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP), a company focused on developing and out-licensing its disruptive drug delivery platform DehydraTECH™, recently announced the results of its second in vivo study of 2018 evaluating this edible technology’s use as a nicotine delivery system (http://nnw.fm/dmD2T).

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) has developed and out-licenses its proprietary technology for improved taste, rapidity, and delivery of bioactive compounds, including cannabinoids. Though boasting a wide range of health benefits, cannabinoids are traditionally poorly absorbed by the body’s gastrointestinal tract. To achieve higher effectiveness, consumers usually default to smoking. Lexaria provides a superior administration method by delivering hemp oil ingredients – or through locally licensed partners, cannabis oil ingredients – through a patented process within food products.

The key differentiator between Lexaria’s products and others on the market is the company’s disruptive technology proven to enhance the absorption of orally ingested cannabinoids while improving the “unusual” taste of cannabinoids and allowing for lower overall dosing with higher efficacy. Lexaria is primarily a B2B enterprise, and is in licensing discussions or has existing agreements with companies in Canada, the largest-market states in the USA, and internationally. Lexaria has also developed its own brands partly for demonstration purposes, utilizing its patented technology to infuse hemp oil ingredients within lipids in popular foods. These brands include ViPova™, Lexaria Energy Foods, and TurboCBD™.

In 2015, Lexaria commissioned an independent, third-party lab to test its technology under carefully monitored in vitro conditions. Results showed that the company’s technological process and lipid formulation both improve intestinal absorption as much as 500%. Additional follow-up studies in human volunteers suggested that Lexaria’s processed, lipid-infused tea may be more effective in an actual gastrointestinal system than in an in vitro simulation with results indicating as much as a 1,000% increase in overall absorption.

Lexaria also has an R&D partnership with the Canadian government’s National Research Council. That R&D is expected to characterize molecular bond formation theorized to occur with Lexaria’s unique technology between the lipid delivery agents and the bioactive substances it processes and combines. Results from this R&D are expected to support accelerating B2B relationships – not just in the cannabis industry, but also to support new B2B business relationships in the fields of vitamins, NSAIDs, and nicotine delivery. All of these sectors expected to offer additional future growth potential.

Aside from testing, a critical component of Lexaria Bioscience’s business model is a strong intellectual property portfolio that utilizes the most commonly used food processing techniques. As of 2017, the company’s patent portfolio includes 19 patent applications filed and pending in more than 40 countries around the world. The most recent patent applications expand Lexaria’s lipophilic food and beverage composition claims to include the processing of cannabinoids, vitamins, NSAIDs and nicotine in many of the world’s most commonly used food processing ingredients. Lexaria is expecting additional new patent awards both in the USA and internationally in 2017 and 2018.

Royalties play a vital role in Lexaria’s revenue-generating business model. The company out-licenses its technology (royalty) to third party partners, and has several deals signed and/or pending. The company’s growth initiatives are guided by a management team headed by CEO Chris Bunka, a serial entrepreneur who has raised more than $50 million in working capital for the companies he has led over the course of his career. He is supported by a team of professionals with extensive experience in pharmaceutical and bioscience sectors, invention, toxicology, consumer goods, and other relevant skillsets.

Lexaria Bioscience Corp. (LXRP), closed the day's trading session at $2.05, up 0.99%, on 267,865 volume with 247 trades. The average volume for the last 60 days is 218,641 and the stock's 52-week low/high is $0.322/$2.54.

Recent News

chart

NUGL Inc. (OTC: NUGL)

The QualityStocks Daily Newsletter would like to spotlight NUGL Inc. (NUGL).

NUGL (OTC: NUGL), through its flexible web app technology, is providing the cannabis community with the first software application to offer sophisticated, in-depth marketing and networking capabilities. To view the full article, visit: http://nnw.fm/J3l1y.

NUGL Inc. (OTC: NUGL) is focused on leading the evolution in business relations, development and organic data in the cannabis industry with a distinct platform. In this effort, it has developed a leading-edge, first of its kind search app and online directory for the marijuana industry that provides a one-stop source and listings for dispensaries, strains, doctors, lawyers, service professionals, vape shops, hydro stores and brands.

Headquartered in Chino Hills, California, which is home to a projected $5 billion legal marijuana marketplace, NUGL is on track to become a major asset for the global cannabis industry and related services sectors. The company recently established a strategic partnership with Thinklogic and appointed CEO Chris Adams to NUGL’s growing board of directors. Thinklogic is a top-level software development company specializing in projects for start-ups to Fortune 500 companies.

“This strategic partnership puts NUGL in a distinguished class, adding a first-rate technical software expert like Chris gives NUGL a unique technological advantage,” said Brandon Vargas CEO of NUGL. “With the addition of Chris’s knowledge and expertise combined with Thinklogics’ experienced and skilled staff, NUGL will have the ability to evolve and build a strong infrastructure unmatched in the 420 industry.”

NUGL is nearing completion of its initial launch timeline, with plans to launch the app on both Android and iOS platforms within the next few weeks. NUGL’s live testing of its software includes enhanced reviews that detail up to 10 category ratings. Each of the category rankings allow users to leave comments and choose among a 5-star rating among all categories or as few as they wish. The software’s rating platform allows for customization and transparency for users while providing invaluable feedback to shops and professional services.

“This is a major feature that is critical to our community,” said Jeff Odle, NUGL’s CTO. “Enhanced ratings will be a definitive difference validating our organic listings and raising the standard for the industry. We want the users to know what they are getting before they step into a store or sign up for a service.”

Leadership Team

NUGL is growing its team of developers and launching new features on an ongoing basis. The company is ahead of an impressive timeline, which includes building blocks for scalability and massive growth.

“Everything we do is focused on user experience. Our philosophy is simple – make it fun and easy to use, with the purest and most unbiased results,” said Ryan Bartlette, NUGL CMO. “As the industry evolves and becomes more sophisticated, NUGL will adapt and build the best marketing technology for the cannabis-related companies. We have gotten in on the ground level and know the pulse of the industry.”

NUGL CEO Brandon Vargas is a founding member of G6 Management, a full-service consulting firm advising cannabis professionals in all aspects of business. With over 10 years’ experience in the cannabis space, he has worked on dispensary, cultivation and infusion entity formation, licensing, real estate acquisitions, construction and build out, marketing, policy and procedures, compliance, staffing, and capital raises. Vargas has an extensive background working with various medical marijuana companies on investment and in developing greenhouse and commercial cultivation, distillate for vapes cartridges, CBD oils and infusions.

CMO Ryan Bartlette is co-founder and CMO of 23Forty LLC and Boxy. He has expertly positioned and branded many companies while bringing them to market and is a sought out graphic artist, front-end developer, photographer, and visual artist with experience in the entertainment and technology industry.

Jeff Odle, NUGL CTO, is a successful senior software architect has a long and distinguished career developing some of the most innovative, cutting-edge platforms available. His unique and distinctive approach to creating the blueprint for advanced programming is industry leading and unprecedented. He is a top-level architect responsible for developing some of the most forward-­looking software for various industries.

NUGL’s board of directors includes John R. Armstrong, a founding partner of Horwitz + Armstrong, a full service general business firm handling all aspects of litigation and business strategy and advice. Armstrong and his partner, Lawrence Hortwitz, have more than 10 years of experience in the cannabis space, representing cannabis professionals in all aspects of business including business formation, licensing, compliance with local and state regulations, real estate acquisitions, corporate mergers and acquisitions, financing, inclusive of capital raises and alternative financing, contracts, and all forms of dispute resolution.

Board member Hendrik Klein, founder of Da Vinci Asset Management, a privately-owned investment firm, serves as CEO and executive board member of Fritz Nols AG, a capital marketing consulting firm specializing in trading and asset management. Klein has received several industry awards including the Austrian Hedge Fund Award, the German Hedge Fund Award, and most recently was named the Global Best Performing Systematic Quantitative CTA. Klein and the Da Vinci team employ the latest quantitative data research and analysis in their innovative investment strategy.

NUGL Inc. (NUGL), closed the day's trading session at $1.39, even for the day, on 67,469 volume with 42 trades. The average volume for the last 60 days is 121,325 and the stock's 52-week low/high is $0.405/$1.80.

Recent News

chart

Medical Cannabis Payment Solutions (OTC: REFG)

The QualityStocks Daily Newsletter would like to spotlight Medical Cannabis Payment Solutions (REFG).

Medical Cannabis Payment Solutions (OTC: REFG), through its Green platform, is offering an end-to-end management system to its clients operating in the cannabis industry. To view the full article, visit: http://nnw.fm/kp5QV.

Medical Cannabis Payment Solutions (OTC: REFG), headquartered in Cheyenne, Wyoming, is a first-tier merchant processing cannabis industry pioneer, offering one of the first and only comprehensive card processing operations of its kind to serve the state-sanctioned medical marijuana industry. The company’s state of the art system, which also tracks sales and tax collection, and eliminates the need to deal in cash-only transactions.

Through its robust, closed-loop merchant processing system, the company’s unique “StateSourced” proprietary system enables authorized operation under FinCEN parameters and complies with all regulatory frameworks. StateSourced is tailored to deliver full-spectrum merchant processing services, providing the convenience of modern commercial card processing resources and making it the first operation of its kind geared to the legal cannabis industry.

StateSourced is not a prepaid or gift card, which is an important variable for merchants since standard banking institutions have not offered this form of payment processing to the legal cannabis industry. Federal law still considers marijuana illegal under the Controlled Substances Act, although 29 states and the District of Columbia have legalized the plant either for medicinal or recreational uses or both. This restriction has kept financial institutions at bay since most banks are federally insured and haven’t been inclined to venture into the nascent industry.

Medical Cannabis Payment Solutions is able to offer its StateSourced card on a state-by-state basis where the card can be used in purchasing product from a legal, authorized vendor, providing a much-needed option for consumers and businesses alike. In another first, the company is collaborating with First Bitcoin Capital Corporation to integrate First Bitcoin’s cryptocurrency ($Weed) with Medical Cannabis Payment Solutions’ StateSourced payment gateway. This collaboration will allow state-licensed marijuana establishments across the nation to accept both StateSourced debit cards and cryptocurrencies such as WeedCoin and Bitcoin.

Medical Cannabis Payment Solutions president and CEO Jeremy Roberts and his executive team are working with state lawmakers to introduce legislation in an effort to address the growing problems in banking for the medical cannabis industry. For companies in the emerging legal cannabis industry, where retail and non-retail transactions such as vendor payments and payroll are almost exclusively paid for with cash, the solutions offered by StateSourced can help businesses avoid the inherent risks associated with a cash-intensive sector. Medical Cannabis Payment Solutions has also signed its first StateSourced contract with a Las Vegas-based vertically integrated marijuana establishment.

“We’ve completed our transition from development stage to revenue stage,” says Roberts. “We have just started our business development efforts and the market is responding very well. We anticipate having many more, similar releases.”

Medical Cannabis Payment Solutions provides end-to-end management across multiple systems for medicinal marijuana operations. The company solves the fragmentation problem experienced by many of these rapidly growing companies by identifying tools that are important to dispensaries and customizing those tools to meet the specific needs of this unique industry.

Medical Cannabis Payment Solutions (REFG), closed the day's trading session at $0.035, off by 2.78%, on 156,114 volume with 28 trades. The average volume for the last 60 days is 306,029 and the stock's 52-week low/high is $0.0161/$0.092.

Recent News

chart

Marijuana Company of America Inc. (OTC: MCOA)

The QualityStocks Daily Newsletter would like to spotlight Marijuana Company of America Inc. (MCOA).

Innovative hemp and cannabis corporation Marijuana Company of America Inc. (OTC: MCOA) yesterday issued an update on its joint venture project in New Brunswick, Canada, with partner Global Hemp Group Inc. (CSE: GHG) (OTC: GBHPF). To view the full press release, visit: http://cnw.fm/7uP6d.

Marijuana Company of America Inc. (OTC: MCOA) (the “Company”) are pioneers in the cannabis industry going back to 2009 when Don Steinberg, MCOA’s CEO, founded the first marijuana company ever to trade on a U.S. stock market, Medical Marijuana Inc. Since then, Don and his partner, Charlie Larsen, have formed Global Hemp Group and Marijuana Company of America. They have experienced the shift of legislation first hand, not only for the legalization of marijuana but also the emerging hemp-based CBD products.

The CBD market is growing exponentially and consequently the founders of MCOA have constructed their business model around the development of industrial hemp-based CBD products. The industrial hemp plant can be used to produce products that are carbon neutral or even carbon negative. It is one of the longest, strongest natural fibers on earth, used as a building material that is free of mold, pesticide-resistant, and fire proof. Hemp has also been described as a “super food,” which provides additional business opportunities. No part of the plant is left unused and the Company’s overall strategy is to take advantage of every profit center from farm to the multiple valuable finished products.

The cannabis and hemp industries are experiencing unprecedented growth that is expected to continue for many years as these industries are now accepted globally and continue to mature and expand. North American consumers spent $6.7 billion on legal cannabis products in 2016, up 34% from 2015’s $5 billion. This trend is widely expected to explode at a 27% compounded annual growth rate to reach $22.6 billion by 2021, according to ArcView Market Research.

The company offers investors the opportunity to be on the forefront of cannabis and hemp innovation through cultivation, processing in the legal cannabis and industrial hemp sectors. The Company’s business model includes producing a diverse portfolio of synergistic business segments that provide value to its shareholders. Its vertically integrated business model and distribution platforms are positioned to capture market share by developing recognizable and valuable brands.

Under the MCOA umbrella, wholly owned subsidiary hempSMART™, Inc. is committed to bringing high quality CBD-based products to the market through its affiliate marketing program. Through hempSMART, MCOA’s strategic approach to the distribution of products is through a networking architecture geared to maintain customer loyalty and capture market share. The patent-pending product “hempSMART Brain,” is designed to revolutionize the safe and effective support of healthy brain function. The brand new product, HempSMART DROPS, is a full-spectrum CBD tincture formulated with hemp and fractionated coconut oils. The hempSMART marketing team has decades of experience, and is well positioned to take the hempSMART brand to a global audience.

Marijuana Company of America Inc. (MCOA), closed the day's trading session at $0.0347, off by 1.70%, on 6,146,197 volume with 457 trades. The average volume for the last 60 days is 7,966,372 and the stock's 52-week low/high is $0.022/$0.0728.

Recent News

chart

PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H)

The QualityStocks Daily Newsletter would like to spotlight PreveCeutical Medical Inc. (PRVCF).

Health sciences company PreveCeutical Medical (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) holds a wide array of advanced therapeutic products in its development pipeline, including its Sol-gel delivery platform. To view the full article, visit: http://nnw.fm/C0znX.

PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE:18H), headquartered in Vancouver, British Columbia, Canada, is a health sciences company dedicated to researching and developing innovative options for preventive and curative therapies utilizing organic and Nature Identical™ products. The company is strategically staking out select positions in the medically acute areas of diabetes and obesity, pain management, neurological disorders and cancer.

PreveCeutical Medical Inc. had its beginnings in 2009 when Stephen Van Deventer, a seasoned businessman and venture capitalist, and Kimberly Van Deventer, a successful entrepreneur, met and formed a business partnership. The duo created Cornerstone Global Partners, a venture capital and business development company, and became involved in numerous ventures including building companies such as Aurora Cannabis Inc. Taking their interest in the health and wellness market further, the pair began researching how nature and science can work together to benefit health-conscious consumers. Coining and trademarking the word “PreveCeutical” – a combination of the words “preventive” and “pharmaceutical” – was a precursor to the company’s formation and incorporation in October 2015.

The company’s first product was developed in the Dominican Republic and is now marketed and distributed worldwide by PreveCeutical. It is a Caribbean Blue Scorpion venom product sold under the trade name CELLB9®. This product is an oral dilute solution infused with select peptides sourced exclusively from the blue scorpion (Rhopalurus princeps) found only in Caribbean nations. The active potentiated ingredients in CELLB9, which have been used in over 40 countries for over a decade, appear to support health at a deep, cellular level. PreveCeutical’s research team is using proprietary chemistry to generate Nature Identical™ peptides derived from natural compounds found in Caribbean Blue Scorpion venom with the goal of eventually treating, regulating and preventing cancer progression. Peptides are also being used to target an array of disease indications including metabolic disorders, pain management, cancers, cardiovascular and infectious diseases.

PreveCeutical is developing the first nose-to-brain delivery system of cannabinoids (CBDs) with a novel process that prepares insoluble drug-containing nano-micelles and successfully incorporating them into a proprietary sol-gels application, essentially creating a targeted drug delivery vehicle. Intended for use via a nasal spray, this unique formulation rapidly gels upon contact with mucosal tissue, which paves the way for direct nose-to-brain delivery. This novel application eliminates first pass metabolism (stomach, intestines, liver), potentially improving bioavailability and delivering extended time release formulations that may alleviate side effects of higher dosage therapeutics. This CBD-based patented formula is projected to be deployed in selected markets with licensed medical marijuana companies within 18 months.

PreveCeutical is working with four leading Australian research centers to develop a curative therapy for diabetes and obesity. This four-year program involves engineering a novel approach that selectively targets the gene that encodes for the protein PTP-1B, which is implicated and over-expressed in both type-2 diabetes and obesity. PreveCeutical’s gene-silencing technology would effectively “turn off” the genetic signal which leads to the over-production of this key protein molecule, bringing it back down to safe, normalized levels, and prevent the body from storing excessive fat. Diabetes kills one person every six seconds, with more than $800 billion spent globally on the disease.

Another exciting joint venture, established with Sports 1 Marketing, will focus on the therapeutic potential in the peptides and proteins connected to the Caribbean Blue Scorpion venom to potentially treat mild brain injury concussions. Developing a therapeutic product geared towards athletes who suffer from concussions could help alleviate suffering experienced by those who are affected by head trauma.

PreveCeutical Medical’s science and research team is led by Dr. Harendra (Harry) Parekh, Ph.D., who is based at the University of Queensland’s (UQ) Pharmacy Australia Centre of Excellence (PACE), and Dr. Makarand Jawadekar, Ph.D., whose 28 years of R&D experience with Pfizer Inc., is applicable in his role as chief science officer. Research collaborators include Dr. Rakesh Veedu, an emerging expert internationally in the field of molecular medicine, and Professor Grant Ramm, who is currently head of a leading medical research institute located in Brisbane, Australia.

PreveCeutical Medical is partnering with leading industry experts and companies in its quest to be a leader in the preventive health sciences sector. Its Research and Development partnership with UniQuest, the main commercialization company for the University of Queensland, provides PreveCeutical with the rights to all intellectual property arising from projects created under the agreement. PreveCeutical Medical Inc.’s management team brings an extensive portfolio of research experience, product development, deep corporate strategy and capital markets leadership to the company’s core.

PreveCeutical Medical Inc. (PRVCF), closed the day's trading session at $0.02928, off by 2.16%, on 191,629 volume with 30 trades. The average volume for the last 60 days is 651,255 and the stock's 52-week low/high is $0.002/$0.20.

Recent News

chart

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

ActionStockPicksAgressive StocksBetting On Wall StreetCannabisNewsWireGot Stocks?Got Stock Tips?Green Car StocksGreen Energy StocksGreen On The StreetHomeRunStocksMissionIRMissionIR MediaMissionPRMissionSMRNetworkNewsWireQualityStocks MediaQStocksQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsStock BeatsStocks To Buy NowTerrificStocksTiny GemsTip.usTouchdownStocksDaily ToutTraderPower

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.